Phase 2 weight loss (48 weeks): 17.1% at 4 mg maintenance 8 mg Weeks 912 Strong therapeutic dose with substantial appetite suppression and metabolic improvements
doi: 10.1038/sj.jid.5700951
Like KPV, BPC is not FDA approved and is sold through a gray market
Features that may occur in association with attacks of acute porphyria and that should increase suspicion for the diagnosis include systemic arterial hypertension, tachycardia, constipation, and hyponatremia (due to syndrome of inappropriate antidiuretic hormone 180 Section IV
CAT No: 10-101-343 CAS No: 1401708-83-5 Synonyms/Alias: dihexa;1401708-83-5;L-Isoleucinamide, N-(1-oxohexyl)-L-tyrosyl-N-(6-amino-6-oxohexyl)-;N-hexanoic-Tyr-Ile-(6) aminohexanoic amide;9WYX65A5C2;PNB-0408;(2S,3S)-N-(6-amino-6-oxohexyl)-2-[[(2S)-2-(hexanoylamino)-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanamide;6-(2-(2-Hexanamido-3-(4-hydroxyphenyl)propanamido)-3-methylpentanamido)hexanamide;6-[(2S,3S)-2-[(2S)-2-hexanamido-3-(4-hydroxyphenyl)propanamido]-3-methylpentanamido]hexanamide;Hexanoyl-Tyr-Ile-Ahx-NH2;UNII-9WYX65A5C2;Dihexa (PNB-0408)?;DTXSID701032895;GLXC-25923;ATH-1001;AKOS040759118;CS-6864;DA-62870;HY-16969;PNB-0408
Free delivery over $100 and crypto payments make it handy for mixed orders
